Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
IntroductionIn the UK and Ireland, severe and complex obesity is managed in specialist weight management services (SWMS), which provide multicomponent lifestyle interventions to support weight loss, and use of medication if available. Liraglutide 3 mg (LIRA 3 mg) is an effective weight-loss medicati...
Main Authors: | David Webb, Mike Lean, Werd Al-Najim, Barbara McGowan, Dimitris Papamargaritis, Jonathan Lim, James Crane, Carel le Roux, Donal O'Shea, John Wilding |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/2/e034137.full |
Similar Items
-
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
by: Dimitris Papamargaritis, et al.
Published: (2021-02-01) -
An evaluation study of methadone prescribing : a portfolio of study, practice and research
by: McGowan, C. Susanne
Published: (1998) -
Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01) -
Liraglutids viktminskningseffekt
by: Hazime, Zahraa
Published: (2020) -
Liraglutide-Induced Hepatotoxicity
by: Yaakov Maor, et al.
Published: (2021-01-01)